Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the “Classical” Patient
Table 4
Univariate Kaplan-Meier and Cox-regression analysis of ten-year overall survival and event-free survival according to different characteristics of all high-grade osteosarcoma.
Overall survival
Event-free survival
Patients
10 years in %
RRb
Patients
10 years in %
RRb
(%)
(95% CIa in %)
(95% CIa)
(%)
(95% CIa in %)
(95% CIa)
Year of diagnosis
0.010
0.003
1975–1979
64 (15)
27 (17–38)
1.7 (1.2–2.4)
59 (17)
27 (16–39)
2.0 (1.3–3.0)
1980–1989
121 (29)
36 (27–44)
1.6 (1.1–2.1)
91 (27)
33 (24–43)
1.7 (1.2–2.4)
1990–1999
103 (24)
46 (36–55)
1.2 (0.8–1.6)
81 (24)
43 (32–54)
1.4 (0.9–2.0)
2000–2009
136 (32)
47 (37–56)
1
109 (32)
49 (39–59)
1
Gender
0.605
0.433
Female
178 (42)
43 (36–51)
1
134 (39)
45 (37–53)
1
Male
246 (58)
39 (32–45)
1.1 (0.8–1.4)
206 (61)
36 (30–43)
1.1 (0.8–1.5)
Axial versus extremity
<0.001
<0.001
Extremity
309 (73)
47 (41–53)
1
248 (73)
46 (39–52)
1
Axial
115 (27)
23 (16–32)
2.1 (1.6–2.7)
92 (27)
25 (16–34)
2.1 (1.6–2.8)
Primary metastasis
<0.001
No
337 (80)
48 (43–54)
1
Yes
84 (20)
11 (6–19)
3.1 (2.4–4.1)
Age
<0.001
<0.001
≤40 years
297 (70)
50 (44–56)
1
244 (72)
47 (41–53)
1
>40 years
127 (30)
18 (12–26)
2.7 (2.1–3.5)
96 (28)
21 (13–30)
2.5 (1.8–3.3)
Tumour size
0.005
0.035
≤10 cm
186 (54)
50 (43–57)
1
168 (58)
47 (39–54)
1
>10 cm
158 (46)
38 (30–45)
1.5 (1.1–2.0)
120 (42)
35 (26–45)
1.4 (1.0–1.9)
Duration of symptoms
0.542
0.444
≤3 months
206 (53)
45 (38–52)
1
163 (53)
42 (34–49)
1
>3 months
180 (47)
38 (31–45)
1.1 (0.8–1.4)
146 (47)
38 (30–46)
1.1 (0.8–1.5)
Pathologic fracture
0.119
0.492
No
365 (86)
42 (37–47)
1
297 (87)
40 (35–46)
1
Yes
59 (14)
34 (22–46)
1.3 (0.9–1.8)
43 (13)
36 (22–51)
1.2 (0.8–1.7)
ALP
<0.001
0.001
Normal
166 (55)
51 (43–58)
1
148 (62)
49 (40–57)
1
Elevated
135 (45)
26 (18–33)
2.0 (1.5–2.7)
89 (38)
29 (20–39)
1.8 (1.3–2.4)
LDH
<0.001
0.020
Normal
160 (56)
48 (40–56)
1
85 (38)
47 (39–55)
1
Elevated
126 (44)
28 (20–36)
1.7 (1.3–2.3)
139 (62)
30 (20–40)
1.5 (1.1–2.1)
Adequate chemotherapy
<0.001
<0.001
Yes
249 (59)
57 (50–63)
1
198 (58)
56 (48–62)
1
No
170 (40)
17 (12–23)
3.4 (2.7–4.4)
137 (40)
17 (11–24)
3.9 (3.0–5.2)
Uncertain
5 (1)
40 (5–75)
1.2 (0.4–3.9)
5 (1)
40 (5–75)
2.1 (0.8–5.7)
Adequate surgery
<0.001
<0.001
Yes
305 (72)
55 (49–60)
1
277 (81)
48 (41–53)
1
No
108 (25)
4 (2–10)
7.0 (5.4–9.2)
53 (16)
6 (2–14)
4.9 (3.5–6.8)
Uncertain
11 (3)
9 (1–33)
2.9 (1.5–5.6)
10 (3)
0
3.4 (1.8–6.6)
Adequate primary treatment
<0.001
<0.001
Yes
216 (51)
65 (58–71)
1
188 (55)
58 (50–65)
1
No
202 (47)
15 (10–21)
4.8 (3.7–6.2)
147 (43)
18 (12–24)
4.3 (3.2–5.7)
Uncertain
6 (2)
29 (4–61)
2.0 (0.7–5.5)
5 (2)
17 (1–52)
2.8 (1.1–6.9)
Formal inclusion in trial
<0.001
<0.001
Yes
170 (40)
59 (51–66)
1
144 (42)
55 (47–63)
1
No
254 (60)
28 (23–34)
2.4 (1.9–3.2)
196 (58)
29 (22–35)
2.5 (1.8–3.3)
Confidence interval, brelative risk, and clog rank test.
